Abstract Details

Title Candidates for Long Term Anticoagulation Among Hospitalized Patients with Atrial Fibrillation in United States

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S53 - Stroke Prevention (4:18 PM-4:30 PM)

Poster/Presentation
Number 005

Objective

To provide national estimate of eligible hospitalized patients with AFib who could benefit from long-term anticoagulation.

Background Long-term anticoagulation has been consistently shown to reduce the rate of ischemic stroke among selected patients with AFib. There is paucity of data regarding number of eligible patients with AFib in US who could benefit from long-term anticoagulation.

Design/Methods We analyzed data from Nationwide Inpatient Sample (NIS) for the year 2016. We identified patients with primary or secondary diagnosis of AFib who were aged 75 years or greater, women aged 65-74 years, men aged 65-74 years with history of(h/o) ischemic stroke/transient cerebral ischemia(TIAs),and patients aged 18-64 years with AFib and ischemic stroke/TIAs (CHA2DS2-VASc score of 2 or greater) who were hospitalized and discharged alive to provide national estimates.

Results

A total of 871,391 patients (163,236 aged between 18-64 years, 216,645 aged between 65-74 years, and 491,107 aged 75 years or greater) were admitted with a diagnosis of AFib in 2016.The number of patients with AFib who also had h/o ischemic stroke/TIAs was 38,051 (4.37%).Of the AFib patients, aged 75 years or greater, 25,050 (2.87 %) had a h/o ischemic stroke/TIAs.Of the patients aged 65-74 years, 3,534 women (0.41%) and 4,341 men (0.50%) had h/o ischemic stroke/TIAs. Also, there were 91,364 (10.48%) women between age 65-74 years who had AFib but did not have stroke.5,117 (=n,0.59%) patients between age 18-64 years had AFib and h/o stroke/TIAs.The total number of potentially eligible patients with AFib who could benefit from the anticoagulation (based on CHA2DS2-VASc) was 564,030(65% of all patients admitted with AFib).

Conclusions

Over half a million hospitalized patients with AFib who are under medical care can benefit from long-term anticoagulation.Most are stroke free at time of hospitalization in United States and thus associated death and disability from new strokes can be prevented by timely initiation of long-term anticoagulation.

Authors/Disclosures
Nitish Kumar, MD PRESENTER	Dr. Kumar has nothing to disclose.
Vamshi Balasetti, MD (Washington University St Louis School of Medicine)	No disclosure on file
Iryna Lobanova, MD, PhD (JFK medical center)	Iryna Lobanova has nothing to disclose.
	No disclosure on file
Nitish Kumar, MD	Dr. Kumar has nothing to disclose.
Brandi R. French, MD (University of Missouri)	Dr. French has nothing to disclose.
Farhan Siddiq, MD	Dr. Siddiq has nothing to disclose.
Camilo R. Gomez, MD, FAAN (University of Missouri)	Dr. Gomez has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.

��ɫ��

��ɫ��